All In Biotech

Drug Trial Radar · NCT00124982

Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-Biologic DMARDs Who Have an Inadequate Response to Anti-TNF Therapy and Have Limited Therapeutic Options

Last checked: Nov 20, 2026Latest source record: Feb 27, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,286

Actual

Start

Apr 2005

Primary completion

Aug 2009

Study completion Aug 2009

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jul 29, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to summarize the safety and tolerability of abatacept during 6 months of combined treatment with one or more of the background non-biologic disease modifying anti-rheumatic drugs (DMARDs) approved for rheumatoid arthritis (RA) in subjects with active RA. Secondary objectives assessed the clinical efficacy of combination treatment, including disease activity, physical function, and quality of life outcomes.

Conditions

  • Rheumatoid Arthritis

Interventions

  • AbataceptDrug

    IV solution, IV infusion, between 500mg and 1gram based on body weight, monthly, 6 months.

  • Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)Drug

    During the study, subjects continued to receive 1 or more background non-biologic DMARDs (e.g. methotrexate, leflunomide) at the dose level(s) and regimen(s) administered at the time of abatacept treatment onset (Day 1).

  • Anti-Tumor Necrosing Factor (TNF) TherapyDrug

    Any of the anti-TNF therapies (Infliximab, Adalimumab, Etanercept, etc.)administered at the approved label dose for at least 3 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to DiscontinuationsTime frame: Days 1-169
  2. Short-term Period: Number of Participants With AEs of Special InterestTime frame: Days 1-169
  3. Short-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) CriteriaTime frame: Days 1-169
  4. Short-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA CriteriaTime frame: Days 1-169
  5. Short-term Period: Number of Participants With Electrolyte Laboratories Meeting MA CriteriaTime frame: Days 1-169
  6. Short-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA CriteriaTime frame: Days 1-169
  7. Short-term Period: Mean Change From Baseline in Systolic and Diastolic Blood PressureTime frame: Day 1 (Baseline) -Day 169
  8. Short-term Period: Number of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Responses by Enzyme-Linked Immunosorbant Assay (ELISA)Time frame: Days 1-169
  9. Long-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to DiscontinuationsTime frame: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept
  10. Long-term Period: Number of Participants With AEs of Special InterestTime frame: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept
  11. Long-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) CriteriaTime frame: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept
  12. Long-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA CriteriaTime frame: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept
  13. Long-term Period: Number of Participants With Electrolyte Laboratories Meeting MA CriteriaTime frame: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept
  14. Long-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA CriteriaTime frame: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept
  15. Long-term Period: Change From Baseline in Hemoglobin (HGB), Total Protein, and Albumin Over TimeTime frame: BL, Day 365, Day 729
  16. Long-term Period: Change From Baseline in Hematocrit Over TimeTime frame: BL, Day 365, Day 729
  17. Long-term Period: Change From Baseline in Erythrocytes Over TimeTime frame: BL, Day 365, Day 729
  18. Long-term Period: Change From Baseline in Platelets (PLT) Over TimeTime frame: BL, Day 365, Day 729
  19. Long-term Period: Change From Baseline in White Blood Cells Over TimeTime frame: BL, Day 365, Day 729
  20. Long-term Period: Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and G-Glutamyl Transferase (GGT) Over TimeTime frame: BL, Day 365, Day 729
  21. Long-term Period: Change From Baseline in Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, Calcium (Ca), Phosphorus (P), Serum Glucose (Glu), and Uric Acid Over TimeTime frame: BL, Day 365, Day 729
  22. LT; Change From Baseline in Sodium (Na), Potassium (K), Chloride (Cl) Over TimeTime frame: BL, Day 365, Day 729
  23. Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over TimeTime frame: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept
  24. Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over TimeTime frame: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept
  25. Long-term Period: Mean Heart Rate (HR) Over TimeTime frame: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept
  26. Long-term Period: Mean Temperature (T) Over TimeTime frame: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept

Locations

148 sites in 10 countries. Site status is shown where the registry gives one.

  • Local Institution

    Birmingham, Alabama

  • Local Institution

    Huntsville, Alabama

  • Local Institution

    Paradise Valley, Arizona

  • Local Institution

    Peoria, Arizona

  • Local Institution

    Tucson, Arizona

  • Local Institution

    Long Beach, California

  • Local Institution

    Palm Springs, California

  • Local Institution

    Palo Alto, California

  • Local Institution

    San Diego, California

  • Local Institution

    Santa Monica, California

  • Local Institution

    Colorado Springs, Colorado

  • Local Institution

    Denver, Colorado

  • Local Institution

    Danbury, Connecticut

  • Local Institution

    Hamden, Connecticut

  • Local Institution

    Trumbull, Connecticut

  • Local Institution

    Washington D.C., District of Columbia

  • Local Institution

    Aventura, Florida

  • Local Institution

    Clearwater, Florida

  • Local Institution

    Fort Lauderdale, Florida

  • Local Institution

    Jupiter, Florida

  • Local Institution

    Largo, Florida

  • Local Institution

    Sarasota, Florida

  • Local Institution

    Atlanta, Georgia

  • Local Institution

    Blue Ridge, Georgia

  • Local Institution

    Macon, Georgia

  • Local Institution

    Morton Grove, Illinois

  • Local Institution

    Evansville, Indiana

  • Local Institution

    Indianapolis, Indiana

  • Local Institution

    Des Moines, Iowa

  • Local Institution

    Kansas City, Kansas

  • Local Institution

    Prairie Village, Kansas

  • Local Institution

    Bowling Green, Kentucky

  • Local Institution

    Louisville, Kentucky

  • Local Institution

    New Orleans, Louisiana

  • Local Institution

    Boston, Massachusetts

  • Local Institution

    Peabody, Massachusetts

  • Local Institution

    Springfield, Massachusetts

  • Local Institution

    Worcester, Massachusetts

  • Local Institution

    Ann Arbor, Michigan

  • Local Institution

    East Lansing, Michigan

Showing 40 of 148 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.